Rhythm(US:RYTM) Globenewswire·2025-10-21 20:01Core Viewpoint - Rhythm Pharmaceuticals, Inc. is set to report its third quarter 2025 financial results and provide a corporate update on November 4, 2025, at 8:00 a.m. ET [1] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [3] - The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for treating obesity related to specific genetic conditions [3][4] - Setmelanotide is indicated for patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or deficiencies in POMC, PCSK1, or LEPR [4][5] Upcoming Events - Rhythm will host a live conference call and webcast for its financial results on November 4, 2025 [1] - The company will also participate in two fireside chats on November 12, 2025, at the Guggenheim Healthcare Innovation Conference and the Stifel Healthcare Conference [7] Product Indications - In the U.S., setmelanotide is indicated for long-term weight reduction in patients with specific genetic obesity conditions [4] - In the EU and UK, it is indicated for obesity treatment and hunger control associated with genetically confirmed BBS or related deficiencies [5] Limitations and Contraindications - Setmelanotide is not indicated for obesity due to benign variants of POMC, PCSK1, or LEPR [6][8] - Serious hypersensitivity reactions have been reported, contraindicating its use in patients with prior serious hypersensitivity to the drug [9] Warnings and Precautions - Patients may experience disturbances in sexual arousal, depression, and hypersensitivity reactions [10][11][12] - Skin hyperpigmentation and the development of new melanocytic nevi have been observed, necessitating regular skin examinations [13] Adverse Reactions - Common adverse reactions (≥20% incidence) include skin hyperpigmentation, injection site reactions, nausea, headache, and depression [15]